Performance of the BioPlex 2200 multiplexing immunoassay platform for the detection of herpes simplex virus type 2 specific antibodies in African settings.
LeGoff, Jérôme;
Grésenguet, Gérard;
Gody, Chrysostome;
Longo, Jean De Dieu;
Khonde, Nzambi;
Weiss, Helen A;
Mayaud, Philippe;
Bélec, Laurent;
ANRS 12-12 Study Group;
(2011)
Performance of the BioPlex 2200 multiplexing immunoassay platform for the detection of herpes simplex virus type 2 specific antibodies in African settings.
Clinical and vaccine immunology, 18 (7).
pp. 1191-1193.
ISSN 1556-6811
DOI: https://doi.org/10.1128/CVI.05003-11
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
The BioPlex platform was evaluated for the detection of herpes simplex virus 2 (HSV-2) antibodies in sub-Saharan Africa individuals in comparison to clinicovirological standards and compared to HerpeSelect. The sensitivities and specificities were, respectively, 88.9% and 93.5% for BioPlex and 89.9% and 92.7% for HerpeSelect. The agreement between both assays was 95.7%.
